Top line accelerating.
+44.7% YoY versus +32.0% prior. 3y CAGR +31.7%.
+44.7%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $1.03T
Live price unavailable
Fundamentals as of 2025-12-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
Strength. Revenue +56% to $19.8B with Mounjaro +125% and a 44.7% operating margin — the obesity franchise is compounding at a scale rarely seen in pharma.
Risk. At ~40x trailing earnings, the price already pays for the build-out — and realized prices fell ~13% even as volume soared +65%.
Mixed — Eli Lilly and Company has 77.8% ROE but D/E 3.24.
Financial story
Mixed — Eli Lilly and Company's 77.8% ROE is strong, but its 3.24 debt-to-equity is elevated.
Bottom line: LLY is flagged as overvalued by the 1 legendary model, but earns a C sector grade (56/100) in Healthcare. Use the per-tab analysis to form your own view. Drill into the valuation breakdown and sector ranking for the full picture.
LLY's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
LLY is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
0 of 6 legendary investor models rate LLY a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Eli Lilly and Company's fair value depends on which model you trust. See the per-investor fair-value table in the valuation tab.
LLY trades at 40.4x earnings. Sector context and per-investor signals are in the valuation tab.
LLY and JNJ differ on P/E, ROE, and revenue growth. See the full LLY vs JNJ compare matrix.
How does LLY compare?
See exactly where LLY ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingLLY sits at #28 in Healthcare with a C grade (56/100).
+44.7% YoY versus +32.0% prior. 3y CAGR +31.7%.
+44.7%Net margin 31.7% versus 23.5% prior (+8.2pp). Operating 45.6%.
31.7%P/E 40.2x — 27% below the 5y median of 55.4x. Forward 30.9x hints at EPS expansion next year.
40.2x